Stockscreener 앱 받기
17.09
0.70%
-0.12
시간 외 거래:
17.09
전일 마감가:
$17.21
열려 있는:
$16.85
하루 거래량:
405.66K
Relative Volume:
1.81
시가총액:
$301.04M
수익:
$116.88M
순이익/손실:
$-25.09M
주가수익비율:
-77.68
EPS:
-0.22
순현금흐름:
$-20.74M
1주 성능:
-9.62%
1개월 성능:
-29.70%
6개월 성능:
+78.92%
1년 성능:
+38.94%
1일 변동 폭
$16.85
$17.76
1주일 범위
$16.68
$19.80
52주 변동 폭
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
17.09 | 301.04M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop - Simply Wall St
Rigel to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
(RIGL) Trading Signals - Stock Traders Daily
Rigel Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year - Yahoo Finance
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique - GlobeNewswire Inc.
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are still up 50% over 1 year despite pulling back 26% in the past week - Simply Wall St
Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline - The Globe and Mail
Rigel to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - The Malaysian Reserve
Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright - MarketBeat
Rigel Pharmaceuticals announces initial data from Phase 1b study of R289 - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
(RIGL) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Jacobs Levy Equity Management Inc. Has $2.87 Million Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - MarketBeat
Rigel Pharmaceuticals, Inc. Appoints Keith A. Katkin to its Board of Directors - Marketscreener.com
PDT Partners LLC Purchases New Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA - TipRanks
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS - PR Newswire
Rigel Pharma's Blood Disorder Drug R289 Wins FDA Fast Track Status for MDS Treatment - StockTitan
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Decline in Short Interest - MarketBeat
How To Trade (RIGL) - Stock Traders Daily
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
SEC Form 4 filed by CEO, President Rodriguez Raul R - Quantisnow
Warm Autoimmune Hemolytic Anemia Market to Observe Stupendous Growth During the Forecast Period (2020-2034) | Rigel Pharmaceuticals, Bioverativ (Sanofi), Incyte, Johnson & Johnson - The Globe and Mail
Rigel Pharmaceuticals, Inc. Appoints Dean Schorno as Executive Vice President and Chief Financial Officer - Marketscreener.com
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus.com
Rigel Pharmaceuticals : Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update - Marketscreener.com
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% - MSN
Rigel Pharmaceuticals To Present At Jefferies London Healthcare Conference; Webcast At 4:30 AM ET - Nasdaq
(RIGL) Proactive Strategies - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Reduces Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $33.38 Average PT from Analysts - MarketBeat
Rigel Pharmaceuticals price target raised to $23 from $15 at Piper Sandler - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00 at Piper Sandler - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia
Rigel Pharmaceuticals price target raised to $49 from $40 at Citi - TipRanks
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges - Investing.com
Citi raises Rigel Pharma stock target, buy rating on strong Gavreto sales - Investing.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Rigel stock rallies 36% after Q3 earnings beat - MSN
Rigel Pharmaceuticals stock hits 52-week high at $17.5 By Investing.com - Investing.com Australia
Earnings call: Rigel Pharmaceuticals reports strong Q3 growth, plans expansion - Investing.com Canada
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rigel Pharmaceuticals 주식 (RIGL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Santos David A | EVP, Chief Commercial Officer |
Feb 02 '24 |
Sale |
1.13 |
5,601 |
6,329 |
358,011 |
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '24 |
Sale |
1.14 |
7,027 |
8,011 |
402,891 |
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 02 '24 |
Sale |
1.13 |
5,601 |
6,327 |
409,918 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '24 |
Sale |
1.14 |
30,545 |
34,821 |
2,036,629 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 02 '24 |
Sale |
1.13 |
22,349 |
25,261 |
2,067,174 |
2.88%
2.65%
자본화:
|
볼륨(24시간):